Werkgroep Cardiologische centra Nederland

SOS-AMI (Recruiting)

Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Medicine
Selatogrel
Population
ASCVD
Phase
III
Starting year
2020

Director of Study

dr. R.M. Oemrawsingh (Cardioloog)
Breda, Amphia Ziekenhuis